Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), a global pharmaceutical company incorporated in Ireland, filed this Current Report on August 11, 2021. The filing announces the release of earnings results for the second quarter ended July 3, 2021. The detailed financial data is contained in the attached press release (Exhibit 99.1) and is not explicitly restated within the body of this 8-K form.
Key Financial Metrics
This filing serves as a notification of earnings release and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document outlines the methodology for calculating non-GAAP financial measures, which exclude items such as impairment charges, amortization expense, restructuring charges, and acquisition-related costs to better reflect underlying operational trends.
Material Changes and Adjustments
The filing details specific adjustments made to derive non-GAAP results for the three and six months ended July 3, 2021, compared to prior periods. Key adjustments include:
- Amortization expense related to acquired intangible assets.
- Acquisition and integration-related charges and contingent consideration adjustments.
- Unusual litigation and impairment charges.
- Restructuring charges, separation, and reorganization expenses.
- Foreign currency translation movements.
- Exclusion of net sales from specific divested or acquired businesses (e.g., Ranir, Dr. Fresh, Eastern European Brands, Rosemont Pharmaceuticals, and the Animal Health business) to facilitate organic growth comparisons.
Guidance, Outlook, and Management Commentary
Management utilizes these non-GAAP measures for planning, forecasting, and evaluating segment performance. The company emphasizes that these measures allow investors to compare performance against peers and understand trends without the impact of foreign exchange or one-time events. No specific forward-looking guidance or numerical outlook is provided in this text; investors are directed to the attached press release for full commentary.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP revenue, net income, and EPS figures.
- Verify the reconciliation between GAAP and non-GAAP measures to understand the impact of excluded items like amortization and restructuring.
- Confirm the impact of foreign currency translation on reported growth rates.
- Check for details on the "unusual litigation" and "impairment charges" mentioned as adjustments.
- Assess the organic growth metrics by excluding the impact of the Ranir, Dr. Fresh, and Eastern European Brands acquisitions.